Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells

Cancer Research

Volumn 73, Issue 7, 2013, Pages 2052-2058

  Casetti, Luana ^a,b   Martin Lanneree, Severine ^a,b   Najjar, Imen ^a,b   Plo, Isabelle ^c   Auge, Sylvie ^a,b   Roy, Lydia ^d   Chomel, Jean Claude ^d   Lauret, Evelyne ^a,b   Turhan, Ali G ^d   Dusanter Fourt, Isabelle ^a,b  

^a INSTITUT COCHIN   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Universite Paris Sud   (France)

^d POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; IMATINIB; MESSENGER RNA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER STEM CELL; CELL ISOLATION; CELL PROTECTION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CHRONIC MYELOID LEUKEMIA; CLONOGENESIS; CONTROLLED STUDY; DISEASE ACTIVITY; DNA DAMAGE; ENZYME STRUCTURE; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; HEMATOPOIETIC STEM CELL; HUMAN; MOLECULARLY TARGETED THERAPY; MUTANT; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT5A GENE; STAT5B GENE; TRANSACTIVATION;

APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; HEMATOPOIETIC STEM CELLS; HUMANS; HYDROGEN PEROXIDE; IMMUNOENZYME TECHNIQUES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; OXIDATIVE STRESS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; STAT5 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 84876008261     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3955     Document Type: Article

References (20)

1. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
2. Chomel JC, Bonnet ML, Sorel N, Bertrand A, Meunier MC, Fichelson S, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011;118:3657-60.
3. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
4. Ilaria RL Jr, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996;271:31704-10.
5. Schepers H, van Gosliga D, Wierenga AT, Eggen BJ, Schuringa JJ, Vellenga E. STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. Blood 2007;110:2880-8.
6. Scherr M, Chaturvedi A, Battmer K, Dallmann I, Schultheis B, Ganser A, et al. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 2006;107: 3279-87.
7. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000;95:2118-25.
8. Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 2011; 117:3409-20.
9. Hennighausen L, Robinson GW. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev 2008;22:711-21.
10. Wierenga AT, Vellenga E, Schuringa JJ. Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels. Mol Cell Biol 2008;28:6668-80.
11. Amsellem S, Ravet E, Fichelson S, Pflumio F, Dubart-Kupperschmitt A. Maximal lentivirus-mediated gene transfer and sustained transgene expression in human hematopoietic primitive cells and their progeny. Mol Ther 2002;6:673-7.
12. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011;121: 396-409.
13. Sallmyr A, Fan J, Datta K, Kim KT, Grosu D, Shapiro P, et al. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood 2008;111:3173-82.
14. Urao N, Ushio-Fukai M. Redox regulation of stem/progenitor cells and bone marrow niche. Free Radic Biol Med 2012;54C:26-39.
15. Cholez E, Debuysscher V, Bourgeais J, Boudot C, Leprince J, Tron F, et al. Evidence for a protective role of the STAT5 transcription factor against oxidative stress in human leukemic pre-B cells. Leukemia 2012.
16. Harir N, Pecquet C, Kerenyi M, Sonneck K, Kovacic B, Nyga R, et al. Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood 2007; 109:1678-86.
17. Kazansky AV, Kabotyanski EB, Wyszomierski SL, Mancini MA, Rosen JM. Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A. J Biol Chem 1999;274: 22484-92.
18. Sebastian C, Herrero C, Serra M, Lloberas J, Blasco MA, Celada A. Telomere shortening and oxidative stress in aged macrophages results in impaired STAT5a phosphorylation. J Immunol 2009;183: 2356-64.
19. Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E, et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 2009;27:3642-9.
20. Kluza J, Jendoubi M, Ballot C, Dammak A, Jonneaux A, Idziorek T, et al. Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells. PLoS One 2011;6:e21924.